683 results on '"AMBROSE, CHRISTOPHER"'
Search Results
2. Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review
3. Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
4. Gaps in Care Among Uncontrolled Severe Asthma Patients in the United States
5. Geographic variation in disease burden among patients with severe persistent asthma in the United States
6. Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review
7. At-home asthma mortality unchanged despite declining mortality in other settings: US death certificate data (2000-2019)
8. Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results
9. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study
10. Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: Findings from CHRONICLE
11. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)
12. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma
13. Journal update monthly top five
14. Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma
15. Biologic use and outcomes among adults with severe asthma treated by US subspecialists
16. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy
17. Efficacy of Biologics in Patients With Moderate-to-Severe, Uncontrolled Asthma and Nasal Polyps
18. Efficacy of Biologics in Patients With Severe, Uncontrolled Asthma by Allergic Status
19. Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma With Aspirin-exacerbated Respiratory Disease: Results From the NAVIGATOR Study
20. Exacerbation Rate Reductions With Biologic Use Among US Subspecialist-Treated Adults With Severe Asthma by Age Group: Results From the CHRONICLE Study
21. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments
22. Real-World Assessment of Asthma Specialist Visits Among U.S. Patients with Severe Asthma
23. Geographic variation in disease burden among patients with severe persistent asthma in the United States
24. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma
25. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
26. RSV and non-RSV illness hospitalization in RSV immunoprophylaxis recipients: A systematic literature review
27. Associations Between Individual Characteristics and Blood Eosinophil Counts in Adults with Asthma or COPD
28. An expert consensus framework for asthma remission as a treatment goal
29. MORTALITY AMONG ADULTS WITH SUBSPECIALIST-TREATED SEVERE ASTHMA: RESULTS FROM THE CHRONICLE STUDY
30. LONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX
31. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH ASTHMA AND PERSISTENT AIRFLOW OBSTRUCTION: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES
32. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES
33. At-Home Asthma Mortality Unchanged Despite Declining Mortality in Other Settings: US Death Certificate Data (2000-2019)
34. Characteristics of exacerbations in patients with severe, uncontrolled asthma who received tezepelumab versus placebo
35. Tezepelumab can restore normal lung function in patients with severe, uncontrolled asthma
36. National and regional modeling of distinct RSV seasonality thresholds for antigen and PCR testing in the United States
37. Differential Attacks on Deterministic Signatures
38. Reply to Lipworth and Chan
39. Incremental cost burden among patients with severe uncontrolled asthma in the United States
40. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials
41. Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review
42. 2015–2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States
43. Biologic outcomes in US Hispanic and Black patients with severe asthma
44. Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond
45. Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma
46. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014–2015 season
47. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2–49 years
48. Association of vaccine handling conditions with effectiveness of live attenuated influenza vaccine against H1N1pdm09 viruses in the United States
49. Racial and Ethnic Disparities in Treatment of Uncontrolled Disease Among Severe, Persistent Asthma Patients: An Analysis of Medicare Fee-for-Service Claims
50. Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.